Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice
-
Published:2024-04-15
Issue:4
Volume:20
Page:e1012132
-
ISSN:1553-7374
-
Container-title:PLOS Pathogens
-
language:en
-
Short-container-title:PLoS Pathog
Author:
Bristol Jillian A.,
Nelson Scott E.,
Ohashi Makoto,
Casco Alejandro,
Hayes Mitchell,
Ranheim Erik A.,
Pawelski Abigail S.,
Singh Deo R.,
Hodson Daniel J.,
Johannsen Eric C.,
Kenney Shannon C.ORCID
Abstract
Epstein-Barr virus (EBV) is an important cause of human lymphomas, including Burkitt lymphoma (BL). EBV+ BLs are driven by Myc translocation and have stringent forms of viral latency that do not express either of the two major EBV oncoproteins, EBNA2 (which mimics Notch signaling) and LMP1 (which activates NF-κB signaling). Suppression of Myc-induced apoptosis, often through mutation of the TP53 (p53) gene or inhibition of pro-apoptotic BCL2L11 (BIM) gene expression, is required for development of Myc-driven BLs. EBV+ BLs contain fewer cellular mutations in apoptotic pathways compared to EBV-negative BLs, suggesting that latent EBV infection inhibits Myc-induced apoptosis. Here we use an EBNA2-deleted EBV virus (ΔEBNA2 EBV) to create the first in vivo model for EBV+ BL-like lymphomas derived from primary human B cells. We show that cord blood B cells infected with both ΔEBNA2 EBV and a Myc-expressing vector proliferate indefinitely on a CD40L/IL21 expressing feeder layer in vitro and cause rapid onset EBV+ BL-like tumors in NSG mice. These LMP1/EBNA2-negative Myc-driven lymphomas have wild type p53 and very low BIM, and express numerous germinal center B cell proteins (including TCF3, BACH2, Myb, CD10, CCDN3, and GCSAM) in the absence of BCL6 expression. Myc-induced activation of Myb mediates expression of many of these BL-associated proteins. We demonstrate that Myc blocks LMP1 expression both by inhibiting expression of cellular factors (STAT3 and Src) that activate LMP1 transcription and by increasing expression of proteins (DNMT3B and UHRF1) known to enhance DNA methylation of the LMP1 promoters in human BLs. These results show that latent EBV infection collaborates with Myc over-expression to induce BL-like human B-cell lymphomas in mice. As NF-κB signaling retards the growth of EBV-negative BLs, Myc-mediated repression of LMP1 may be essential for latent EBV infection and Myc translocation to collaboratively induce human BLs.
Funder
National Institutes of Health
Cancer Research UK Cambridge Institute, University of Cambridge
Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge
CRUK and EPSRC Cancer Imaging Centre in Cambridge and Manchester
NIHR Cambridge Biomedical Research Centre
Publisher
Public Library of Science (PLoS)
Reference99 articles.
1. Epstein-Barr virus: Biology and clinical disease;B Damania;Cell,2022
2. EBV Persistence—Introducing the Virus;DA Thorley-Lawson;Curr Top Microbiol Immunol,2015
3. Epstein-Barr virus latency: current and future perspectives;B Kempkes;Curr Opin Virol,2015
4. Epstein-Barr Virus and Cancer;PJ Farrell;Annu Rev Pathol,2019
5. Burkitt Lymphomas Evolve to Escape Dependencies on Epstein-Barr Virus;RL Hutcheson;Front Cell Infect Microbiol,2020